SCYNEXIS, Inc. (SCYX)
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic
$0.99
-1.23%
Mkt Cap $36.09M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 4, 2026 | $8.10M | $18.65M | +130.20% | $0.13 | $0.25 | +97.32% | — | — |
| Q4 2025 Nov 5, 2025 | $8.10M | $334.00K | -95.88% | -$0.21 | -$0.17 | +19.05% | — | — |
| Q3 2025 Aug 13, 2025 | $154.00K | $1.36M | +785.71% | -$0.23 | -$0.14 | +39.13% | — | — |
| Q2 2025 May 15, 2025 | $137.00K | $257.00K | +87.59% | -$0.23 | -$0.17 | +26.09% | — | — |
| Q1 2025 Mar 12, 2025 | $10.19M | $977.00K | -90.41% | -$0.22 | -$0.09 | +59.09% | — | — |
| Q4 2024 Nov 6, 2024 | $9.23M | $660.00K | -92.85% | -$0.20 | -$0.06 | +70.00% | — | — |
| Q3 2024 Aug 8, 2024 | $12.23M | $736.00K | -93.98% | -$0.19 | -$0.30 | -57.89% | — | — |
| Q2 2024 May 8, 2024 | $5.35M | $1.37M | -74.34% | -$0.18 | -$0.15 | +16.67% | — | — |
| Q1 2024 Mar 28, 2024 | $1.37M | $5.80M | +323.14% | $0.31 | -$0.39 | -225.81% | — | — |
| Q4 2023 Nov 13, 2023 | $1.37M | $1.76M | +28.54% | $0.29 | -$0.04 | -113.79% | — | — |
| Q3 2023 Aug 14, 2023 | $95.45M | $131.45M | +37.72% | $1.55 | $2.46 | +58.71% | — | — |
| Q2 2023 May 11, 2023 | $90.40M | $1.13M | -98.75% | -$0.28 | -$0.25 | +10.71% | — | — |
| Q1 2023 Mar 31, 2023 | $1.57M | $1.52M | -2.93% | -$0.50 | -$0.29 | +42.00% | — | — |
| Q4 2022 Nov 9, 2022 | $2.11M | $1.56M | -26.19% | -$0.51 | -$0.62 | -21.57% | — | — |
| Q3 2022 Aug 15, 2022 | $1.68M | $1.32M | -21.17% | -$0.57 | -$0.53 | +7.02% | — | — |
| Q2 2022 May 12, 2022 | $1.09M | $687.00K | -36.97% | -$0.74 | -$0.51 | +31.08% | — | — |
| Q1 2022 Mar 29, 2022 | $1.26M | $597.00K | -52.59% | -$0.71 | -$1.05 | -47.89% | — | — |
| Q4 2021 Nov 10, 2021 | $893.53K | $516.00K | -42.25% | -$0.79 | -$0.06 | +92.41% | — | — |
| Q3 2021 Aug 16, 2021 | $370.00K | — | — | -$0.58 | -$0.22 | +62.07% | — | — |
| Q2 2021 May 17, 2021 | $18.82M | $12.05M | -35.97% | -$0.68 | -$0.23 | +66.18% | — | — |